The effect of 3,4-dichloropropionaniline (DCPA) treatment on collagen-induced arthritis (CIA) at 40 days. The effect of 3,4-dichloropropionaniline (DCPA)

Slides:

Advertisements

Similar presentations

Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced.

Advertisements

The genomic region spanning rs shows enhancer activity.

Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

The groove model of osteoarthritis applied to the ovine fetlock joint

Representative histopathology images from the knee joints and ankle of CAIA mice injected s.c. with GalNAc–MASP-3–siRNA duplex 2 or GalNAc–luciferase–siRNA.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Fluorescence-stained images and respective bright-field images of mouse spleen tissue sections area investigated using Raman spectroscopy. Fluorescence-stained.

Protective effects of a cathepsin K inhibitor, SB , in the canine partial medial meniscectomy model of osteoarthritis J.R. Connor, C. LePage, B.A.

Percentage of patients achieving EULAR response

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Endochondral bone formation in HLA-B27 transduced ATDC5 micromasses.

FTIR measurements from cortical and trabecular bone of rat tibia on day 22 post disease induction. FTIR measurements from cortical and trabecular bone.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Mean values of CANDEN spine inflammation score and for vertebral body and posterior elements subscores, bars represent the SEM; as observed (n=49, 47,

Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ttw mice reported in figure.

Radiological findings on the development of ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in famotidine-treated.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Frequency of patients in flare at each time point over 3 months

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the proportion of patients receiving CZP from.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Effect of collagen-induced arthritis (CIA) and 3,4-dichloropropionaniline (DCPA) on osteoclast bone interface density determined by ATPa3 (TCIRG) labelling,

Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.

CAIA is attenuated in Nrdc – / – mice.

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Foot maps showing the patterns of average tissue stress, peak tissue stress, urate deposition in gout and bone erosion in gout. Foot maps showing the patterns.

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

Changes in microRNA expression on treatment of RASF for 2 weeks with 20 mM L-methionine or betaine. Changes in microRNA expression on treatment of RASF.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

Effect of CIA and treatment with 3,4-dichloropropionaniline (DCPA) on production of key serum inflammatory factors. Effect of CIA and treatment with 3,4-dichloropropionaniline.

Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. (A)

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Clinical response in patients with early and established RA at month 24. *p

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

IL-6-dependent changes in preclinical phase of arthritis in gp130F759.

The earliest pathological changes of arthritis in gp130F759 develop at 5 months of age. The earliest pathological changes of arthritis in gp130F759 develop.

The clinical and histological changes of arthritis in gp130F759.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.

Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.

Clinical paradigms and pathogenetic explanations.

(A and B) Changes in the levels of DNA methyltransferases (DNMTs) transcripts on treatment of RASF for 2 weeks with 20 mM L-methionine (A) or betaine (B).

Distribution of swelling and tenderness in joints with or without x-ray progression. Distribution of swelling and tenderness in joints with or without.

DAS28-CRP change from baseline over 24 weeks (TP1 per-protocol set) at baseline, the mean DAS28-CRP was 5.42 and 5.53 for GP2015 and ETN groups, respectively.

MRI, STIR sequence of sacroiliac joints (SIJs): minimal localised signal increase on both sides of the upper part of the left SIJ (arrows), which does.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Schematic depiction of categories of inflammation in 350 small joints during progression from clinically suspect arthralgiato inflammatory arthritis. Schematic.

Mean profiles over 1 year from the observed Disease Activity Score 28 (DAS28) data for the methotrexate (MTX)-exposed patients after stratifying by predicted.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.

Administration of anti-glial cell line-derived neurotrophic factor (anti-GDNF) antibodies reduces liver fibrosis development in mice. Administration of.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Intra-articular Nrdc gene silencing with siRNA attenuates CAIA

Toll-like receptor 4 (TLR4)-knockout (KO) mice were partially protect against rotenone-induced enteric glial inflammation and α-syn expression in the colon.

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Antibody treatment ameliorates inflammation in experimental arthritis.

Presentation transcript:

The effect of 3,4-dichloropropionaniline (DCPA) treatment on collagen-induced arthritis (CIA) at 40 days. The effect of 3,4-dichloropropionaniline (DCPA) treatment on collagen-induced arthritis (CIA) at 40 days. (A–C) The top frame shows an ankle bone in an untreated animal (untreated control, histological score 0). The middle frame shows severe arthritis in CIA treated with 0 mg/kg/day DCPA, with severe synovial inflammation, pannus in the joint space and severe bone degradation (histological damage score 8). The bottom frame shows the results from CIA animals treated with 21 mg/kg/day; there is inflammation, with synovial thickening, but it is not severe (histological damage score 4). All fields are 1.2 mm across. (D) Severity of arthritis in each group scored by a blinded observer based on sections as in A–C. The histological joint damage index (HJDI) in CIA animals treated with 21 mg/kg/day DCPA (yellow bar) is statistically different from those treated with 0 mg/kg/day (blue bar), p=0.024. The untreated group was different from all other groups, p<0.01. The CIA animals treated with 10.5 mg/kg/day (green bar) were poorly separated on day 40 HJDI, and were not studied further. Both hind feet of each animal were individually processed and blindly scored, so the number of measurements is twice the number of animals and expressed as the mean±SEM HJDI. Animal numbers are as stated for figure 1. (E) Anti-type II collagen titre in CIA mice. The anti-type II collagen titre in CIA animals treated with 21 mg/kg/day DCPA (yellow bar) was 8.3 (±2.8)×103 and was not statistically different from those treated with 0 mg/kg/day (mean titre=7.1 (±2.1) × 103; blue bar). The mean anti-type II collagen titre of CIA animals treated with 10.5 mg/kg/day (green bar) was 5.1 (±1.1) × 103 and also was not statistically different from the other CIA animals. The anti-type II collagen titres in the untreated group were all below the level of detection. Values shown are the respective group mean±SEM. Harry C Blair et al. RMD Open 2016;2:e000093 Copyright © BMJ Publishing Group & EULAR. All rights reserved.